Simon Allen

Chief Executive Officer and Director

At Ambrx, Mr. Allen established multiple partnerships with companies including Bristol Myers Squibb, Pfizer, Merck, Eli Lilly, Astellas, BeiGene and Sino Biopharma that have generated more than $270 million in revenue with a potential $1 billion in future milestones and royalties. From 2016 to 2018 he was Chief Executive Officer of CohBar, where he transitioned the company from the preclinical to the clinical stage and managed the listing of its shares on Nasdaq, with subsequent inclusion in the Russell 2000 Index. Earlier Mr. Allen held various management, commercial and business development positions at Nuvelo, Skyepharma, CovX and Kalypsys.

Mr. Allen started his career as a research biologist in the antiviral group at Gilead Sciences before working in healthcare equity research and investment banking in the U.S. and Australia. He holds a BSc in biochemistry and genetics from the University of Sydney and an MBA from the Australian Graduate School of Management.

Dr. Kenneth Cundy, Ph.D.

Chief Scientific Officer

Prior to joining Anebulo, Dr. Cundy served as Chief Scientific Officer at CohBar, Inc., a publicly-traded biotechnology company developing therapeutics targeting chronic and age-related diseases, where he built a technology platform around peptides encoded in the mitochondrial genome, advancing the lead program to successful clinical proof of concept for NASH and obesity. Before CohBar, Dr. Cundy was Chief Scientific Officer at XenoPort, Inc., a biopharmaceutical company focused on therapeutics for neurological disorders. He was coinventor of XenoPort’s approved drug Horizant®, leading efforts from discovery to development including approval for the treatment of postherpetic neuralgia and restless legs syndrome in the US and Japan. Previously, Dr. Cundy held various positions at Gilead Sciences, Inc. where he was coinventor of the blockbuster drug tenofovir DF (Viread®) and a key contributor to the larger antiviral franchise, including Hepsera®, Vistide®, and Tamifu®.

Dr. Cundy started his scientific career at Sterling Winthrop, a pharmaceutical division of Eastman Kodak Company, where he developed novel formulation technologies exploiting Kodak’s historical capabilities. He was coinventor of Nanocrystal® technology used in many approved drug products. Dr. Cundy received a B.S. in pharmacy from the University of Manchester and registered as a pharmacist in the United Kingdom before earning a Ph.D. in pharmaceutical sciences from the University of Kentucky and postdoctoral training in Biochemistry at the University of California, Berkeley.

Sandra Gardiner

Acting Chief Financial Officer

Sandy Gardiner joined Anebulo in March 2023 as Acting Chief Financial Officer.  Prior to joining Anebulo, Ms. Gardiner served as the Chief Financial Officer, Executive Vice President of Finance and Administration and Treasurer of Pulse Biosciences, Inc., a publicly traded medtech company (2019-2022).  She also served as the Secretary of Pulse Biosciences from November 2019 until October 2021. She has held CFO roles in both domestic and global companies, operating as a director to international subsidiaries throughout Europe, Asia Pacific and Latin America. Her tenures include leadership positions at development-stage, pre-commercial to enterprise, and commercial $350M+ biotech and medtech companies. Ms. Gardiner has been involved in executing numerous financial transactions, including IPOs, secondary offerings, private placements, reverse mergers, rights offerings, ATMs and debt facilities.

Ms. Gardiner also served as Chief Financial Officer of Cutera, Inc., Tria Beauty, Inc., Aptus Endosystems, Inc., Ventus Medical, Inc., Vermillion, Inc., and Lipid Sciences, Inc. Earlier in her career, Ms. Gardiner served in roles of increasing responsibility at Cardima, Inc., Comac, Inc. and Advanced Cardiovascular Systems, Inc. Ms. Gardiner currently serves on the Board of Directors of LevitasBio and as Board Chair of the Valley Humane Society. She and previously served on the Board of Directors of Lucira Health Inc. including serving as Audit Committee Chair and a member of the Nominating and Corporate Governance Committee. Ms. Gardiner holds a Bachelor of Arts degree in Management Economics from the University of California, Davis.